This is a preview of subscription content, log in via an institution to check access.
REFERENCE
EMA.Refusal of the marketing authorisation for Qsiva (phentermine / topiramate). Internet Document: [2 pages], 18 Oct 2012. Available from: URL: http://www.ema.europa.eu
Additional information
Key words
Pharmacovigilance; Cardiovascular-disorders; Pregnancy; therapeutic use; In-utero-exposure; Cognition-disorders; Benefit-risk-assessment; adverse reactions; Tachycardia; Teratogenesis; drug-induced; Psychiatric-disorders; treatment; Obesity; Phentermine/topiramate
Rights and permissions
About this article
Cite this article
CHMP recommends against Qsiva approval. React. Wkly. 1426, 4 (2012). https://doi.org/10.2165/00128415-201214260-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201214260-00008